AVAVA, Inc., a pioneering medical aesthetics platform company developing safe and effective image-guided intradermal laser products for all skin tones, has secured $35 million in new financing.
AVAVA, Inc. has successfully concluded its Series C funding round, securing $25 million from both new and existing investors, including strategic partner Jeisys Medical, Inc. Additionally, the company obtained $10 million in growth capital from Catalio Capital Management, LP, known for its investments in healthcare and life sciences.
This financial boost will propel AVAVA forward in executing its global expansion plans and advancing its product pipeline. Particularly, it will accelerate the commercialization of MIRIA, AVAVA’s flagship product, which employs Focal Point Technology™ to deliver precise energy for skin revitalization across all skin tones.
Dr. Irina Erenburg, CEO of AVAVA, expressed enthusiasm about the funding, highlighting the company’s commitment to innovation and dedication to meeting customer needs. Catalio Capital Management emphasized its confidence in AVAVA’s disruptive technology and its long-term strategic partnership with the company.
AVAVA’s platform, developed by renowned dermatology experts, offers safe and effective solutions for diverse skin tones, positioning the company as a leader in medical aesthetics.
About AVAVA: AVAVA, born out of Blossom Innovations, pioneers a new class of intradermal lasers, delivering customized skin care through advanced technology and guided imaging.
About Blossom Innovations: Blossom Innovations, founded by leading dermatology experts, drives clinical innovation with a focus on personalized skin care solutions.
About Catalio Capital Management: Catalio Capital Management is a healthcare and life sciences investment firm backing breakthrough companies and fostering scientific collaboration.
